319460-85-0 Axitinib AKSci J99425
 
 
Loading Please Wait...
  J99425    
Axitinib, 95%, for synthesis
 
N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
Inlyta
IDENTITY
CAS Number:319460-85-0
MDL Number:MFCD09837898
MF:C22H18N4OS
MW:386.47
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%, for synthesis
Physical Form (at 20°C):Solid
Melting Point:211-214°C
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 42mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor recep
Form:Free base

REVIEW
 The vascular endothelial growth factor receptor (VEGFR), a signal protein, is responsible for the origination and progression of various tumours. VEGFR-1 plays a major role in the growth of new blood vessels from the old blood vessels (angiogenesis) and tumour growth. VEGFR-2 plays an important role in the endothelial cell proliferation, migration and survival, and angiogenesis. VEGFR-3 is involved in the formation of new lymphatic vessels from already existing lymphatic vessels (lymphangiogenesis). Axitinib has the ability to inhibit VEGFR-1, 2 and 3 selectively. It binds to the receptors of the VEGF and inhibits it, thereby preventing the formation of new blood vessels.

REFERENCES
[1]Hu-Lowe et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2 and 3. Clin.Cancer Res. 14 7272. PMID: 19010843.
[2] Ma and Waxman (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol.Cancer Ther. 7 79. PMID: 18202011.
[3] Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25(3):319-27
[4] Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Proceedings Abstract 4509.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H302; H410

Precautionary Statements
P264; P270; P273; P301+P312; P330; P391; P501

Current as of March 29, 2023


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES
 APIs and Bioactives > Protein Kinase Inhibitors


PubChem